Major US insurers, such as Aetna, Cigna and United HealthCare, have saidthey will cover the newly-approved abortion pill Mifeprex (mifepristone: see page 19) as a standard benefit, say Associated Press reports.
Mifeprex is different from other new drugs in that it is dispensed directly from a physician's office and not through a pharmacy, which is why the plans are deciding to cover it as a standard medical benefit rather than a drug benefit, the reports note.
Other firms, such as Humana and Kaiser Permanente, have yet to decide to whether or not to cover the drug, while PacifiCare says it will leave the decision to its doctors, because it regards Mifeprex as a new method of performing abortions rather than as a new drug.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze